Rolla, S., De Mercanti, S. F., Bardina, V., Maglione, A., Taverna, D., Novelli, F. ... Clerico, M. (2022). Long-Term Effects of Alemtuzumab on CD4+ Lymphocytes in Multiple Sclerosis Patients: A 72-Month Follow-Up. Frontiers in Immunology, 13.. doi: 10.3389/fimmu.2022.818325
Rolla, Simona, et al. "Long-Term Effects of Alemtuzumab on CD4+ Lymphocytes in Multiple Sclerosis Patients: A 72-Month Follow-Up." Frontiers in Immunology, vol. 13, 2022. https://doi.org/10.3389/fimmu.2022.818325
Rolla, Simona, Stefania Federica De Mercanti, Valentina Bardina, Alessandro Maglione, Daniela Taverna, Francesco Novelli, Eleonora Cocco, et al. "Long-Term Effects of Alemtuzumab on CD4+ Lymphocytes in Multiple Sclerosis Patients: A 72-Month Follow-Up." Frontiers in Immunology 13 (2022). https://doi.org/10.3389/fimmu.2022.818325
Rolla, S., et al. (2022) 'Long-Term Effects of Alemtuzumab on CD4+ Lymphocytes in Multiple Sclerosis Patients: A 72-Month Follow-Up', Frontiers in Immunology, 13. doi: 10.3389/fimmu.2022.818325
Rolla S, De Mercanti SF, Bardina V, Maglione A, Taverna D, Novelli F, i sur.. Long-Term Effects of Alemtuzumab on CD4+ Lymphocytes in Multiple Sclerosis Patients: A 72-Month Follow-Up. Frontiers in Immunology [Internet]. 28.02.2022. [pristupljeno 21.08.2024.];13. doi: 10.3389/fimmu.2022.818325
S. Rolla, et al., "Long-Term Effects of Alemtuzumab on CD4+ Lymphocytes in Multiple Sclerosis Patients: A 72-Month Follow-Up", Frontiers in Immunology, vol. 13, Veljača 2022. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:992905. [Citirano: 21.08.2024.]